HC Wainwright Brokers Lower Earnings Estimates for ProKidney

ProKidney Corp. (NASDAQ:PROK) – Equities researchers at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of ProKidney in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.13) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.39) EPS.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, August 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.19 million.

Several other equities analysts also recently weighed in on PROK. Weiss Ratings upgraded ProKidney from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 10th. Wall Street Zen downgraded ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.00.

ProKidney Price Performance

NASDAQ:PROK opened at $1.48 on Thursday. ProKidney has a 1-year low of $1.41 and a 1-year high of $3.48. The firm’s 50-day moving average price is $1.71 and its 200-day moving average price is $1.88. The company has a market capitalization of $447.05 million, a PE ratio of -2.69 and a beta of 1.66.

Institutional Trading of ProKidney

Several large investors have recently modified their holdings of PROK. Millennium Management LLC bought a new position in ProKidney in the third quarter valued at about $4,734,000. Artia Global Partners LP bought a new position in ProKidney in the fourth quarter worth approximately $4,118,000. JPMorgan Chase & Co. lifted its position in ProKidney by 3,024.9% during the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after purchasing an additional 1,615,243 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of ProKidney by 578.6% during the 4th quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock valued at $2,006,000 after buying an additional 763,705 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of ProKidney in the second quarter worth approximately $350,000. Institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.